Investigation of the Roles of New Antiepileptic Drugs and Serum BDNF Levels in Efficacy and Safety Monitoring and Quality of Life: A Clinical Research

DEMİR M., Akarsu E. O., Dede H. O., BEBEK N., YILDIZ S., Baykan B., ...Daha Fazla

CURRENT CLINICAL PHARMACOLOGY, cilt.15, sa.1, ss.49-63, 2020 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 15 Sayı: 1
  • Basım Tarihi: 2020
  • Doi Numarası: 10.2174/1574884714666190312145409
  • Dergi Adı: CURRENT CLINICAL PHARMACOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Agricultural & Environmental Science Database, Biotechnology Research Abstracts, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.49-63
  • Anahtar Kelimeler: Epilepsy, new antiepileptic drugs, TDM, safety, QOLIE-31, BDNF, efficacy, NEUROTROPHIC FACTOR, PHARMACOKINETIC INTERACTIONS, ILAE-COMMISSION, BRAIN, EPILEPSY, LAMOTRIGINE, EMPLOYMENT, MECHANISM, SEIZURES
  • İstanbul Üniversitesi Adresli: Evet

Özet

Objective: We aimed to determine the therapeutic drug monitoring (TDM) features and the relation to Brain-Derived Neurotrophic Factor (BDNF) of frequently used new antiepileptic drugs (NADs) including lamotrigine (LTG), oxcarbazepine (OXC), zonisamide (ZNS) and lacosamide (LCM). Moreover, we investigated their effect on the quality of life (QoL).